Organization (Industry)
GUARDANT HEALTH, INC.
ClinicalTrials.gov lists GUARDANT HEALTH, INC. as lead sponsor of 10 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Guardant Health, Inc., via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers GUARDANT HEALTH, INC.: 10 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (24)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Colorectal Neoplasms | 11 |
| Lung Neoplasms | 10 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Colonic Neoplasms | 6 |
| Breast Neoplasms | 3 |
Showing 5 of 24 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 4 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 4 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 2 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 40% hit target (n=5) | 60% on time (n=5) |
Journals published in (25)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 4 |
| Annals of the New York Academy of Sciences | 3 |
| Cancer research | 3 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 3 |
| The New England journal of medicine | 3 |
Showing 5 of 25 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 127 | 88 | 2025-12-16 |
SEC-reported annual financials (10)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 982,021,000 | -416,277,000 | 364,191,000 |
| 2024 | 739,016,000 | -436,373,000 | 347,753,000 |
| 2023 | 563,948,000 | -479,449,000 | 367,194,000 |
| 2022 | 449,538,000 | -654,588,000 | 373,807,000 |
| 2021 | 373,653,000 | -384,770,000 | 263,221,000 |
| 2020 | 286,730,000 | not reported | 149,862,000 |
| 2019 | 214,375,000 | -75,651,000 | 86,292,000 |
| 2018 | 90,639,000 | -85,063,000 | 50,714,000 |
| 2017 | 49,842,000 | -83,221,000 | 25,562,000 |
| 2016 | not reported | not reported | not reported |
Financing and grant events (28)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-11-07 | Public offering | 327,200,000 | Sec extracted |
| 2025-11-07 | Debt financing | 390,000,000 | Sec extracted |
| 2025-11-06 | Follow-on offering | 344,999,880 | Edgar offerings |
| 2025-11-04 | Other financing | not disclosed | Edgar offerings |
| 2025-02-14 | Debt financing | 600,000,000 | Sec extracted |
Showing 5 of 28 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| GUARDANT HEALTH, INC (Campus) | Redwood City, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | 53.0% | 33.0% |
Organization relationships (16)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of California System | Co sponsors trial with | 1 |
| Thomas Jefferson University | Co sponsors trial with | 1 |
| Wake Forest University | Co sponsors trial with | 1 |
| George Mason University | Co sponsors trial with | 1 |
| Caris Life Sciences, Inc. | Co sponsors trial with | 1 |
Showing 5 of 16 relationships.
Latest dated events (186)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-22 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-15 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 186 events.
CLIA clinical laboratory certificates (4)
Shown in this order: active first, then certificate type.
| Lab | Certificate | Status |
|---|---|---|
| GUARDANT HEALTH INC | Certificate of accreditation | Active |
| GUARDANT HEALTH INC | Certificate of accreditation | Terminated |
| GUARDANT HEALTH INC | Certificate of registration | Terminated |
| GUARDANT HEALTH INC | Certificate of registration | Terminated |
Biomarker capability evidence (72)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BRAF | Diagnostics manufacturer | FDA-authorized companion diagnostic |
| BRAF | Diagnostics manufacturer | FDA-authorized companion diagnostic |
| EGFR | Diagnostics manufacturer | FDA-authorized companion diagnostic |
| EGFR | Diagnostics manufacturer | FDA-authorized companion diagnostic |
| EGFR | Diagnostics manufacturer | FDA-authorized companion diagnostic |
Showing 5 of 72 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, fda warning letters, fda untitled letters, fda recalls, fda import refusals, and biomarkers this organization publishes on.